|
業務類別
|
Medical Devices |
|
業務概覽
|
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others. |
| 公司地址
| 47071 Bayside Parkway, Fremont, CA, USA, 94538 |
| 電話號碼
| +1 510 626-9888 |
| 傳真號碼
| +1 510 605-5062 |
| 公司網頁
| https://www.alamarbio.com |
| 員工數量
| 222 |
| Mr. Timothy White |
President |
-- |
27/03/2026 |
| Mr. Justin J. McAnear |
Chief Financial Officer and Principal Accounting Officer |
-- |
27/03/2026 |
| Dr. Yuling Luo, PhD |
Chairman of the Board and Chief Executive Officer |
-- |
27/03/2026 |
| Dr. Shiping Chen, PhD |
Chief Operating Officer and Director |
-- |
27/03/2026 |
|
|
| Dr. Nicholas J. Naclerio, PhD. |
Independent Director |
27/03/2026 |
| Ms. Rebecca Chambers |
Independent Director |
27/03/2026 |
| Dr. Yuling Luo, PhD |
Chairman of the Board and Chief Executive Officer |
27/03/2026 |
| Dr. Frank R. Witney,, PhD |
Lead Independent Director |
13/04/2026 |
| Mr. Ian W. Ratcliffe |
Independent Director |
27/03/2026 |
| Dr. Shiping Chen, PhD |
Chief Operating Officer and Director |
27/03/2026 |
|
|
|
|
